Ekadharma International Tbk (EKAD) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Ekadharma International Tbk stock IDR 321, price IDR 312, upside +2.9%, quality 65 out of 100. Rating: fairly valued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 153.00 IDR – 450.00 IDR · fair‑value band 251.42 IDR – 402.48 IDR · the 312.00 IDR price screens below the 320.92 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Ekadharma International Tbk in your weekly email
Every Wednesday you see whether Ekadharma International Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Ekadharma International Tbk, together with its subsidiaries, engages in manufacturing and sale of self-adhesive tapes and related supplementary materials in Indonesia and Malaysia. It operates through Sticking Plaster and Others segments.
Show moreShow less
The company offers lint roller, accessories, industrial tape, packaging products, and cutters; cloth tape/masking tape products; reflective, PVC electrical, and aluminum foil tape; cling wrap, and aluminum foil; kraft tape; OPP tape, including custom, printed, and OPP color tape; and air column bag products.
It also engages in general trading business. The company sells its products under the Daimaru, SUPERFIX, and BESTPACK brands. The company was formerly known as PT Ekadharma Widya Grafika and changed its name to PT Ekadharma International Tbk in 2006.
The company was founded in 1981 and is headquartered in Tangerang, Indonesia. PT Ekadharma International Tbk is a subsidiary of PT Ekadharma Inti Perkasa.
Stock analysis
Ekadharma International Tbk (EKAD) currently trades at 312.00 IDR, while our model-based Fair Value estimate is 320.92 IDR, so the stock looks roughly fairly valued today (gap 2.8%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 282.94 IDR per share, and 3 of the 25 models we run sit above the 312.00 IDR price.
Bear case: the Dividend Discount group reads lowest at 84.29 IDR, and 22 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: 251.42 IDR (bear) to 402.48 IDR (bull), the price of 312.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Basic Materials sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Ekadharma International Tbk reported revenue of 530B IDR in FY2025 versus 630B IDR in FY2021, a compound −4.2%/yr. Reported net income was 53.0B IDR in FY2025, compounding −15.6%/yr from FY2021.
Key figures
Market cap 1.3T IDR (≈ $70.1M) Micro · P/E ratio 2.1 · P/S ratio 0.21 · EPS (TTM) 146.27 IDR · Dividend yield 2.9% · Net margin 10.0% · Return on equity 5.1% · Return on assets (EBIT) 6.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 104% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −41% fair-value upside, at 3%, EKAD screens cheaper than that median.
Fair Value models
Bear251.42 IDRFair Value 320.92 IDRBull402.48 IDR
Price 312.00 IDR · Upside +2.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (118.09 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF220.45 IDR278.54 IDR344.63 IDR82
Growth DCF221.73 IDR273.40 IDR329.46 IDR80
Owner Earnings67.21 IDR80.22 IDR95.02 IDR78
All 25 models by family
DCF Models
FCF DCF220.45 IDR278.54 IDR344.63 IDR82
Owner Earnings67.21 IDR80.22 IDR95.02 IDR78
5Y Revenue Exit182.96 IDR244.60 IDR318.78 IDR74
5Y EBITDA Exit212.54 IDR297.69 IDR392.01 IDR76
5Y P/E Exit226.15 IDR322.10 IDR417.73 IDR71
10Y Revenue Exit196.29 IDR248.43 IDR310.64 IDR68
10Y EBITDA Exit214.19 IDR277.97 IDR354.69 IDR70
10Y P/E Exit221.19 IDR291.56 IDR370.16 IDR65
Earnings-Based
Graham-Dodd103.20 IDR259.98 IDR337.66 IDR65
PEG = 1.047.91 IDR68.45 IDR88.98 IDR57
EPV103.66 IDR112.65 IDR119.85 IDR74
Dividend Discount
Gordon GGM58.27 IDR89.20 IDR116.62 IDR69
DDM Multi-Stage58.27 IDR79.37 IDR97.00 IDR67
Multiples
P/E Multiple239.03 IDR318.71 IDR398.38 IDR63
P/S Multiple193.50 IDR258.00 IDR322.50 IDR58
P/B Multiple1,186 IDR1,582 IDR1,977 IDR55
EV/EBIT206.64 IDR270.06 IDR333.47 IDR66
EV/EBITDA225.96 IDR295.81 IDR365.67 IDR67
EV/Revenue152.18 IDR210.37 IDR268.56 IDR54
Asset-Based
NCAV (Graham)124.40 IDR188.48 IDR235.60 IDR54
Growth DCF
Growth DCF221.73 IDR273.40 IDR329.46 IDR80
Rev-Margin DCF182.96 IDR248.31 IDR320.69 IDR74
Economic Profit
Residual Income225.51 IDR224.60 IDR233.27 IDR76
ROIC Compounder103.66 IDR112.65 IDR119.85 IDR72
Growth Earnings
Growth-Adj P/E184.63 IDR263.75 IDR342.88 IDR67
The fair value above starts from this blend and is adjusted for a cyclical trough year.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Start year 2020 (pandemic). Over 10 years: +0.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−7.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.7%
Dividend (yield on the price)2.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−10.7% vs 1.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 10%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about −8.1% a year for the price.
Compare Ekadharma International Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 757 stocks
Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+2.9% · Above median
Profitability
Return on equity (12 months)5.1% · Below median
Return on assets3.9% · Above median
Net margin (12 months)10.4% · Above median
Operating margin (12 months)28.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)24.8% · Above median
Dividend yield (12 months)2.9% · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ekadharma International Tbk Fair Value". https://www.fairvalue-calculator.com/stock/EKAD
Frequently asked questions
Is Ekadharma International Tbk (EKAD) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 320.92 IDR versus a price of 312.00 IDR, about +3% upside (fairly valued).
What is the fair value of EKAD?
Our model-based fair value for Ekadharma International Tbk is 320.92 IDR (as of Nov 5, 2026), built from audited fundamentals. The current price: 312.00 IDR.
What is the quality score of EKAD?
Ekadharma International Tbk has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ekadharma International Tbk (EKAD)?
Our model-based price target is the fair value of 320.92 IDR (as of Nov 5, 2026) from 25 valuation models. Cautious scenario 251.42 IDR, optimistic scenario 402.48 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Ekadharma International Tbk stock forecast for 2026?
Our models put fair value at 320.92 IDR, about +3% upside versus a price of 312.00 IDR (fairly valued). Cautious scenario 251.42 IDR, optimistic scenario 402.48 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Ekadharma International Tbk (EKAD)?
Ekadharma International Tbk reported trailing-twelve-month revenue of about 574B IDR (latest available figure, as of Nov 5, 2026).
Does Ekadharma International Tbk pay a dividend?
Ekadharma International Tbk currently shows a dividend yield of 2.88% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Ekadharma International Tbk (EKAD) and when is the ex-dividend date?
Ekadharma International Tbk pays a dividend of 9.00 IDR per share a year, a dividend yield of 2.9%. The last ex-dividend date was Jun 5, 2026. A dividend has been paid every year since at least 2006. The payout ratio is 6.2% of earnings. Free cash flow covers the dividend 2.92 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Ekadharma International Tbk (EKAD)?
For today's price to be fair in a discounted-cash-flow model, Ekadharma International Tbk would have to grow free cash flow by -5.7 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.6 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of EKAD use?
Our models discount Ekadharma International Tbk at 13.5 %: a base by market capitalisation (micro), damped by beta 0.27, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ekadharma International Tbk that is -5.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Ekadharma International Tbk (EKAD) delivered so far?
Over the past 5 years revenue at Ekadharma International Tbk grew -4.6 % a year. The price currently implies free-cash-flow growth of -5.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ekadharma International Tbk (EKAD) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Ekadharma International Tbk (-5.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ekadharma International Tbk (EKAD)?
The free-cash-flow yield on the price is 8.41 %: that much free cash flow Ekadharma International Tbk produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ekadharma International Tbk (EKAD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ekadharma International Tbk it is 320.92 IDR per share (as of Nov 5, 2026), against a price of 312.00 IDR. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Ekadharma International Tbk stock overvalued or undervalued in 2026?
As of Nov 5, 2026, EKAD trades below its calculated fair value: price 312.00 IDR, fair value 320.92 IDR, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EKAD?
No. The price is what the market pays today (312.00 IDR); the fair value is what the company's own numbers justify (320.92 IDR). For Ekadharma International Tbk the two are 8.92 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Ekadharma International Tbk worth?
The market values Ekadharma International Tbk at about 1.3T IDR (market capitalisation, as of Nov 5, 2026). Per share that is 312.00 IDR; our models calculate a fair value of 320.92 IDR per share.
What do the bullish and bearish scenarios say about EKAD?
Our models span a range for Ekadharma International Tbk: cautious scenario 251.42 IDR, base 320.92 IDR, optimistic 402.48 IDR per share (as of Nov 5, 2026, price 312.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EKAD?
Ekadharma International Tbk trades at a price-to-earnings ratio of 2.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 320.92 IDR is built from several models across several years.
How solid is the balance sheet of Ekadharma International Tbk (EKAD)?
Balance-sheet figures for Ekadharma International Tbk (as of Nov 5, 2026): return on equity 5.1%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is EKAD from its 52-week high?
Ekadharma International Tbk trades at 312.00 IDR, about 31% below its 52-week high of 450.00 IDR and 104% above the low of 153.00 IDR (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 320.92 IDR is for.
Which stocks are comparable to Ekadharma International Tbk?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ekadharma International Tbk stock attractive at the current price?
The data as of Nov 5, 2026: price 312.00 IDR, calculated fair value 320.92 IDR (+3%), Quality Score 65/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EKAD calculated?
We run Ekadharma International Tbk through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 320.92 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Ekadharma International Tbk currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ekadharma International Tbk (EKAD)?
The closing price on Nov 10, 2026 was 312.00 IDR. Our model-based fair value is 320.92 IDR, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ekadharma International Tbk right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Ekadharma International Tbk (EKAD) come from?
Earnings per share at Ekadharma International Tbk grew +0.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share −0.3 %, EBIT margin −3.0 %, tax rate +1.4 %, residual (interest, one-offs) +2.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ekadharma International Tbk
How large is the market capitalisation of Ekadharma International Tbk (EKAD)?
The market capitalisation of Ekadharma International Tbk is 1.3T IDR (≈ $70.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ekadharma International Tbk (EKAD)?
The price-to-sales ratio of Ekadharma International Tbk is 0.21 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ekadharma International Tbk (EKAD)?
Earnings per share at Ekadharma International Tbk are 146.27 IDR (price ÷ EPS = P/E 2.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ekadharma International Tbk (EKAD)?
The dividend yield of Ekadharma International Tbk is 2.9% (payout 6.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ekadharma International Tbk (EKAD)?
The net margin of Ekadharma International Tbk is 10.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ekadharma International Tbk (EKAD)?
The return on equity (ROE) of Ekadharma International Tbk is 5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ekadharma International Tbk (EKAD)?
On an EBIT basis the return on assets of Ekadharma International Tbk is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ekadharma International Tbk (EKAD)?
The operating margin of Ekadharma International Tbk is 28.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ekadharma International Tbk (EKAD)?
Revenue at Ekadharma International Tbk is growing +24.8% versus a year earlier (3y avg −4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ekadharma International Tbk (EKAD)?
Earnings per share at Ekadharma International Tbk are growing +67.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Ekadharma International Tbk (EKAD) hold?
Ekadharma International Tbk holds more cash than debt, 57.3B IDR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Ekadharma International Tbk in the live analysis
One click puts Ekadharma International Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026